Neuland Laboratories Limited has informed the Exchange regarding a press release dated July 31, 2025, titled "Press Release on the Financial Results of the Company for the quarter ended June 30, 2025".
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts less than Nifty Smallcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported a weak Q1FY26 with total income falling 32.4% year-on-year to Rs. 300.6 crore from Rs. 444.4 crore in Q1FY25. EBITDA dropped 67.3% to Rs. 42.1 crore, with margins compressing sharply by 1,490 basis points to 14%. Profit after tax declined 86.1% to Rs. 13.7 crore (vs. Rs. 98.3 crore in Q1FY25, which included an exceptional gain of Rs. 20.6 crore from the transfer of an investment property). Management attributed the slump to delayed customer order flow but reiterated its healthy growth outlook for FY26, citing planned investments and strong pipeline progress in commercial molecules and CDMO business.
The sharp YoY decline in revenue, EBITDA, and PAT is likely to weigh negatively on the stock in the near term, though management's confident FY26 outlook and planned capex may provide some support. Investors should watch for order flow recovery in coming quarters.